Skip to NavigationSkip to content

News

0
One in four people worldwide will be obese by 2045 if current trends continue, the possible cause of the most common childhood cancer has been...
0
BioMarin is confident that its newly approved treatment for phenylketonuria is set to become a blockbuster and it’s priced the drug accordingly, at $...
0
AstraZeneca's immunotherapy Imfinzi met its second primary endpoint in the treatment of unresectable Stage III non-small cell lung cancer in...
0
The news broke at the start of the month that a number of women who should have been invited to breast cancer screening had not received their...

Features

Pharmafocus spoke to John Crowley, CEO of Amicus Therapeutics, about his highly unusual career in the pharmaceutical and biotech industries....